Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02936349 · ClinicalTrials.gov registry record
Graded TTCE for Post-Embolization PAVM Monitoring
A clinical trial of Hereditary Hemorrhagic Telangiectasia (HHT), sponsored by University of Pennsylvania.
- Completed
- Registry status
- 32
- Enrollment target
- 1
- Study location
NCT02936349: Completed study of Hereditary Hemorrhagic Telangiectasia (HHT), sponsored by University of Pennsylvania.
NCT02936349 is a study of Hereditary Hemorrhagic Telangiectasia (HHT) that has completed, run by University of Pennsylvania. The registered enrollment target is 32 participants, below the 76-participant average among 3 other Hereditary Hemorrhagic Telangiectasia (HHT) trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02936349, a study of Hereditary Hemorrhagic Telangiectasia (HHT), has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
Current HHT guidelines recommend CT scan to detect new or recurrent PAVMs after embolotherapy. Recent studies using transthoracic contrast echocardiography (TTCE) shunt grade for PAVM screening suggest that graded TTCE can accurately predict the size of PAVMs on chest CT and their amenability to embolization. This study's purpose is to evaluate whether TTCE shunt grade can also accurately predict PAVM size and amenability to treatment in patients who are post-embolization.
Conditions Studied
Interventions
- OTHER Transthoracic Contrast Echocardiogram
Study Locations (1)
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2016-10 |
| Est. Completion | 2019-11 |
What the finished NCT02936349 record still lists
NCT02936349 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 76-participant average among 3 other Hereditary Hemorrhagic Telangiectasia (HHT) trials with a reported enrollment target (58% lower).
The record links to 1 condition, with Hereditary Hemorrhagic Telangiectasia (HHT) appearing as the primary indexed condition, and to 1 intervention - of which Transthoracic Contrast Echocardiogram is the first listed.
NCT02936349 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02936349 about?
NCT02936349 is a clinical study titled "Graded TTCE for Post-Embolization PAVM Monitoring". Current HHT guidelines recommend CT scan to detect new or recurrent PAVMs after embolotherapy. Recent studies using transthoracic contrast echocardiography (TTCE) shunt grade for PAVM screening suggest that graded TTCE can accurately predict the size of PAVMs on chest CT and their amenability to emb...
What is the current status of trial NCT02936349?
This trial is currently completed. The enrollment target is 32 participants. The study started on 2016-10. Estimated completion is 2019-11.
What conditions does trial NCT02936349 study?
This clinical trial studies the following conditions: Hereditary Hemorrhagic Telangiectasia (HHT).
What interventions are being tested in trial NCT02936349?
The interventions under investigation include: Transthoracic Contrast Echocardiogram (OTHER).
Who is sponsoring clinical trial NCT02936349?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02936349 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hereditary Hemorrhagic Telangiectasia (HHT)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia
RECRUITING · Phase 1
-
Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia Longitudinal Assessment Study
ACTIVE NOT RECRUITING
-
Assess Safety and Efficacy of VAD044 in HHT Patients
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia